CEO Stephen O’Hara and director René Kamminga of OptiBiotix Health (LSE:OPTI) present their strategic and commercial update and answer a range of investor questions. The event, held on 8 December 2021, is brought to you by our friends at Investor Meet Company.
About the company
As a life science company, OptiBiotix Health's prime focus lies in researching the area of biotechnology. Its activities include the identification of microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology, deriving potential health benefits. The company markets its products in the UK under trademark names such as OptiBiotix, SweetBiotix, and SkinBioTherapeutics.
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.